Log in to search using one of your social media accounts:

 

Molecular POC Diagnosis of Lower Respiratory InfectionsMolecular POC Diagnosis of Lower Respiratory Infections
Implementing molecular point-of-care testing for lower respiratory infections may enhance quality of care, but is it worth the cost? Future Virology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 27, 2013 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

New Compounds Will Lead To A New Generation Of Anti-Influenza Drugs That The Virus' Strains Can't Adapt To
Simon Fraser University virologist Masahiro Niikura and his doctoral student Nicole Bance are among an international group of scientists that has discovered a new class of molecular compounds capable of killing the influenza virus. Working on the premise that too much of a good thing can be a killer, the scientists have advanced previous researchers' methods of manipulating an enzyme that is key to how influenza replicates and spreads... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 25, 2013 Category: Consumer Health News Tags: Flu / Cold / SARS Source Type: news

Virus shows promise as prostate cancer treatment
(American Society for Microbiology) A recombinant Newcastle disease virus kills all kinds of prostate cancer cells, including hormone resistant cells, but leaves normal cells unscathed, according to a paper published online ahead of print in the Journal of Virology. A treatment for prostate cancer based on this virus would avoid the adverse side effects typically associated with hormonal treatment for prostate cancer, as well as those associated with cancer chemotherapies generally. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 25, 2013 Category: Global & Universal Source Type: news

RCT: nevirapine vs. efavirenz for patients co-infected with HIV and tuberculosis
Source: Lancet Infectious Diseases Area: News Nevirapine and efavirenz are widely used as antiretroviral therapy in countries with high incidence of HIV and tuberculosis co-infection but both drugs interact with antituberculosis drugs. The authors of a study, published online in Lancet Infectious Diseases, compared the efficacy and safety of a nevirapine-based antiretroviral therapy (started at full dose) with an efavirenz-based regimen in co-infected patients receiving antituberculosis medication.   The study was a multicentre, open-label, non-inferiority trial conducted at three health centres in Mozambique. Pa...
Source: NeLM - News - February 22, 2013 Category: Drugs & Pharmacology Source Type: news

Influenza study: Meet virus' new enemy
(Simon Fraser University) Simon Fraser University virologist Masahiro Niikura and his doctoral student Nicole Bance are among an international group of scientists that has discovered a new class of molecular compounds capable of killing the influenza virus. Working on the premise that too much of a good thing can be a killer, the scientists have advanced previous researchers' methods of manipulating an enzyme that is key to how influenza replicates and spreads. Science Express has published the work. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 21, 2013 Category: Global & Universal Source Type: news

Horizon scanning: Phase III (FUSION) results for sofosbuvir in chronic hepatitis C
Source: BioSpace Area: News Gilead Sciences has announced topline results from the phase III FUSION study evaluating sofosbuvir plus ribavirin (RBV) in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus (HCV) infection who failed prior interferon-based treatment.   In the FUSION study, patients were randomised to either a 12-week (n=103) or 16-week (n=98) course of sofosbuvir 400 mg once daily plus RBV (1,000 or 1,200 mg/day). The primary efficacy endpoint was superiority compared to a predefined historic control sustained virological response (SVR) rate of 25%.   The followin...
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news

Virology researcher awarded nearly $2 million to study chronic hepatitis E
(Virginia Tech) A Virginia-Maryland Regional College of Veterinary Medicine scientist has been awarded nearly $2 million from the National Institutes of Health to better understand chronic hepatitis E virus by focusing on patients with chronic infections. The project seeks to develop a chronic hepatitis E model to study how and why the disease progresses into chronicity and its possible medical prevention and treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 19, 2013 Category: Global & Universal Source Type: news

Hepatitis C drug has two modes of action
CHICAGO, Feb. 18 (UPI) -- U.S. and French mathematical modelers, clinicians and molecular virologists say the anti-viral daclatasvir has two modes of action against hepatitis C virus. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 19, 2013 Category: Consumer Health News Source Type: news

Published Work On Respiratory Syncytial Virus In Children From Le Bonheur Children's Hospital
Studies at Le Bonheur are advancing our understanding of how viruses, including RSV, replicate in humans, mutate to avoid the immune response and can be effectively treated. John DeVincenzo, MD, medical director of Molecular Diagnostics and Virology Laboratories at Le Bonheur, and professor of Pediatrics and Microbiology, Immunology, and Molecular Biology at The University of Tennessee Health Science Center, has recently published three papers on this topic. DeVincenzo's lab is one of only two of its kind in the United States... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 18, 2013 Category: Consumer Health News Tags: Infectious Diseases / Bacteria / Viruses Source Type: news

New study on Hepatitis C drug treatment in vivo and in vitro
(Loyola University Health System) An interdisciplinary effort by mathematical modelers, clinicians and virologists has revealed that daclatasvir has two main modes of action against HCV and also yields a more accurate new estimate of the HCV half-life. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 18, 2013 Category: Global & Universal Source Type: news

Microbes team up to boost plants' stress tolerance
(Penn State) While most farmers consider viruses and fungi potential threats to their crops, these microbes can help wild plants adapt to extreme conditions, according to a Penn State virologist. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 17, 2013 Category: Biology Source Type: news

Development of SARS Vaccines and Therapeutics Still NeededDevelopment of SARS Vaccines and Therapeutics Still Needed
The development of vaccines and therapeutics for the prevention and treatment of SARS is still an urgent issue that needs to be addressed. Future Virology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2013 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Seed-borne plant virus diseases(Sastry)
(Source: Springer Biomedical Sciences titles)
Source: Springer Biomedical Sciences titles - February 12, 2013 Category: Biomedical Science Tags: Virology Source Type: news

Newly identified natural protein blocks HIV, other deadly viruses
A team of UCLA-led researchers has identified a protein with broad virus-fighting properties that potentially could be used as a weapon against deadly human pathogenic viruses such as HIV, Ebola, Rift Valley Fever, Nipah and others designated "priority pathogens" for national biosecurity purposes by the National Institute of Allergy and Infectious Disease.   In a study published in the January issue of the journal Immunity, the researchers describe the novel antiviral property of the protein, cholesterol-25-hydroxylase (CH25H), an enzyme that converts cholesterol to an oxysterol called 25-hydroxycholesterol ...
Source: UCLA Newsroom: Health Sciences - February 11, 2013 Category: Universities & Medical Training Source Type: news

Social media may prove useful in prevention of HIV, STDs, study shows
This study helps direct us toward that goal by suggesting that participants will use social media to learn about HIV prevention and that those who talk about HIV prevention over social networking groups are not just talking about it — they are acting on their words by getting an HIV test."   The study also demonstrates that social networking can be a useful tool for collecting and analyzing data, added Young, who is a member of the Center for HIV Identification, Prevention and Treatment Services (CHIPTS) at UCLA.   "Having one platform that allows multiple types of data collection and an...
Source: UCLA Newsroom: Health Sciences - February 6, 2013 Category: Universities & Medical Training Source Type: news

Horizon scanning: Phase III results for sofosbuvir in chronic hepatitis C
Source: BioSpace Area: News BioSpace has reported on the results of two Phase III studies of the investigative antiviral sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) in the first-line treatment of patients with chronic hepatitis C virus (HCV) infection.   In the FISSION study, treatment-naïve patients with HCV genotype 2 or 3 were randomised to receive either 12 weeks of sofosbuvir (400mg once daily) plus ribavirin (1,000 or 1,200 mg/day) (n=256) or standard of care with 24 weeks of pegylated interferon alfa-2a (peg-IFN; 180 mcg/wee...
Source: NeLM - News - February 5, 2013 Category: Drugs & Pharmacology Source Type: news

Switch From Epzicom to Truvada Maintains HIV Suppression: StudySwitch From Epzicom to Truvada Maintains HIV Suppression: Study
Virologic suppression was maintained when HIV patients switched from lamivudine/abacavir (ABC/3TC) to emtricitibine/tenofovir (FTC/TDF) in the pharma-funded SWIFT study. Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 4, 2013 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

U.S. virologists intentionally engineer super-deadly pandemic flu virus
Two American researchers whose efforts to deliberately re-engineer the H5N1 avian flu virus to be more virulent and deadly to humans are now asking that a government-advised moratorium on their controversial research be lifted. According to TIME, the duo alleges that... (Source: NaturalNews.com)
Source: NaturalNews.com - January 31, 2013 Category: Consumer Health News Source Type: news

Disclosure of Maternal HIV Status to ChildrenDisclosure of Maternal HIV Status to Children
When and how should HIV infected mothers disclose their HIV-status to their non-infected children? Future Virology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2013 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Low Vitamin D Levels and HIV-Hepatitis C TherapyLow Vitamin D Levels and HIV-Hepatitis C Therapy
Low vitamin D levels may impair virologic response to PEGIFN + RBV therapy in HIV-hepatitis C patients. AIDS (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 28, 2013 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Man flu: an enigma wrapped in a damp towel | Stuart Jeffries
I'm not sure that research focusing on the preoptic nucleus will settle things – it's really a matter for the psychology of illnessIt's a truth universally acknowledged that men are pathetic. Around this time of year, the man in your life will get the merest sniffle and retire to bed until the middle of next month. He'll take all the toilet rolls, the box set of Game of Thrones and a punchably pitiful look that says, like some Vietnam vet, "You weren't there, man. You wouldn't understand." He'll also take his mobile phone, for reasons that will become clear in a moment.Meanwhile, you will continue heroicall...
Source: Guardian Unlimited Science - January 25, 2013 Category: Science Authors: Stuart Jeffries Tags: Comment Infectious diseases Health guardian.co.uk Medical research Microbiology Society Flu Gender Science Comment is free Source Type: news

Man flu: an enigma wrapped in a damp towel
I'm not sure that research focusing on the preoptic nucleus will settle things – it's really a matter for the psychology of illnessIt's a truth universally acknowledged that men are pathetic. Around this time of year, the man in your life will get the merest sniffle and retire to bed until the middle of next month. He'll take all the toilet rolls, the box set of Game of Thrones and a punchably pitiful look that says, like some Vietnam vet, "You weren't there, man. You wouldn't understand." He'll also take his mobile phone, for reasons that will become clear in a moment.Meanwhile, you will continue heroicall...
Source: Guardian Unlimited Science - January 25, 2013 Category: Science Authors: Stuart Jeffries Tags: Comment Infectious diseases Health guardian.co.uk Medical research Microbiology Society Flu Gender Science Comment is free Source Type: news

IL28B Polymorphisms and Response to Therapy in Chronic HCVIL28B Polymorphisms and Response to Therapy in Chronic HCV
Which biomarkers could potentially help clinicians predict virological responses in patients with chronic hepatitis C? Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Bird flu researchers get green light to continue work on engineered virus
A voluntary moratorium on research involving lab-created versions of the H5N1 bird flu virus has been liftedResearch on lab-engineered strains of the H5N1 bird flu virus is set to restart a year after the scientists voluntarily paused it to allow for an international public debate on the safest way to proceed.Last year, two teams of scientists in the United States and the Netherlands submitted papers for publication in Science and Nature describing how they had engineered the H5N1 bird flu virus – which kills half of the people it infects but cannot naturally transmit from person to person – to spread more easi...
Source: Guardian Unlimited Science - January 23, 2013 Category: Science Authors: Alok Jha Tags: Bird flu Genetics Biology World news Infectious diseases Health guardian.co.uk Medical research Microbiology Society Controversies in science Source Type: news

Systematic review and meta-analysis of clinical use of HIV integrase inhibitors
Source: PLoS One Area: News Integrase inhibitors have swiftly been adopted as part of current antiretroviral regimens. This systematic review and meta-analysis was carried of current evidence regarding the use of these agents in various clinical settings.   A search was conducted of the literature from April 2006 until November 2012, for RCTs and non-RCTs, and cohort studies. A total of 48 unique studies (including 15 abstract-only reports) were included on the use of integrase inhibitors in antiretroviral therapy-naive patients and treatment-experienced patients with either virological failure or switching to in...
Source: NeLM - News - January 17, 2013 Category: Drugs & Pharmacology Source Type: news

Economic savings versus health losses: The cost-effectiveness of generic antiretroviral therapy in the United States
Source: Ann Intern Med Area: News The Annals of Internal Medicine has featured a cost-effectiveness analysis of a 3-pill, generic-based antiretroviral regimen compared with a branded, co-formulated regimen.   U.S. HIV treatment guidelines recommend branded once-daily, 1-pill efavirenz-emtricitabine-tenofovir as first-line antiretroviral therapy (ART). With the anticipated approval of generic efavirenz in the United States, a once-daily, 3-pill alternative (generic efavirenz, generic lamivudine, and tenofovir) will decrease cost but may reduce adherence and virological suppression.   The analysis was base...
Source: NeLM - News - January 16, 2013 Category: Drugs & Pharmacology Source Type: news

Immunological Nonresponse to ART Drugs in HIV InfectionImmunological Nonresponse to ART Drugs in HIV Infection
What is the best approach to treating the immunological nonresponse to ARV drugs in HIV infection? Future Virology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2013 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Systematic review: Effectiveness of antiviral treatment for hepatitis C virus infection in adults
Source: Ann Intern Med Area: News This systematic review compared the safety and efficacy of various antiviral treatments for chronic hepatitis C virus (HCV) infection in treatment-naive adults. The researchers searched Medline, Cochrane, Embase, Scopus, PsychINFO, and clinical trial registries for English-language randomised controlled trials of antiviral treatments and cohort studies examining associations between sustained virological response (SVR) after therapy and clinical outcomes.   The following findings were noted:   . No trial was identified that evaluated effectiveness of treatment on lo...
Source: NeLM - News - January 15, 2013 Category: Drugs & Pharmacology Source Type: news

New strain blamed for record norovirus outbreak
The emergence of a new Australian strain of norovirus – the 'winter vomiting bug' – has featured in most newspapers today. The Daily Telegraph reports that the new strain is to blame for the record number of cases of the virus seen this winter, which it terms a 'severe norovirus season'. Experts have been quick to point out that the new strain of the virus does not cause more serious illness than any other strain. The strain is called Sydney 2012, prompting the Daily Mirror to headline its coverage ‘Down chunder’. Norovirus is contagious and its spread can be prevented by washing hands (particu...
Source: NHS News Feed - January 10, 2013 Category: Consumer Health News Tags: Medical practice QA articles Source Type: news

Seed-borne plant virus diseases(Sastry)
(Source: Springer Biomedical Sciences titles)
Source: Springer Biomedical Sciences titles - January 6, 2013 Category: Biomedical Science Tags: Virology Source Type: news

Two medical pioneers aim to trial a cancer-killing virus. I aim to help out | Alexander Masters
A pair of researchers in Sweden may have a revolutionary cancer treatment on their hands. But a separate revolution will be needed to get it to marketJust north of Stockholm, among the creaking Swedish ice-forests, three revolutions for 2013 are taking place.Revolution One: Two researchers at the University of Uppsala have engineered a virus that will attack cancer. Cheap, precise, with only mild, flu-like side-effects, this plucky little microbe sounds too good to be true. Yet in peer-reviewed articles in top journals, Professor Magnus Essand and Dr Justyna Leja have repeatedly showed that Ad5[CgA-E1A-miR122]PTD views hea...
Source: Guardian Unlimited Science - January 4, 2013 Category: Science Authors: Alexander Masters Tags: Comment The Guardian Crowdsourcing Health Medical research Society Technology Kickstarter Features Cancer Internet Science Comment is free Source Type: news

Alan Rabson Receives AACI Special Recognition Award
The Association of American Cancer Institutes recently honored Alan S. Rabson, M.D., with a Special Recognition Award that recognized his achievements over five decades at the National Cancer Institute, as a deputy director, pathologist, cancer researcher, administrator, and clinical advisor.  The award also celebrates his numerous discoveries in virology and authorship of more than 100 scientific journal articles. Arnold Rabson, M.D., left, accepts the Special Recognition Award from AACI, on behalf of his father. Presenting the award at the Oct. 15 ceremony is AACI President William S. Dalton, M.D., Ph.D., chief exec...
Source: NCI Benchmarks - October 25, 2012 Category: Cancer & Oncology Authors: Aleea Farrakh Khan Tags: cancer Scientist Spotlight award pathology Source Type: news

News: International Conference & Exhibition on Virology
Dates: 5 - 7 September 2011 Venue: Baltimore, USA Website: http://www.omicsonline.org/virology2011/ Operated by: Editors-Journal of Antivirals & Antiretrovirals and Journal of AIDS & Clinical Research Hosting Organization: OMICS Publishing Group OMICS Publishing Group is organizing “International Conference & Exhibition on Virology", will be held during 5-7 September 2011 Baltimore, USA. Virology-2011 is a specially designed cluster conference, which covers a wide range of critically important sessions in basic virology research to Advances in Cancer, Agriculture, Veterinary and Clinical research st...
Source: The Journal of Infection in Developing Countries: Announcements - March 7, 2011 Category: Infectious Diseases Source Type: news

News: International Conference & Exhibition on Virology
Dates: 5 - 7 September 2011 Venue: Baltimore, USA Website: http://www.omicsonline.org/virology2011/ Operated by: Editors-Journal of Antivirals & Antiretrovirals and Journal of AIDS & Clinical Research Hosting Organization: OMICS Publishing Group OMICS Publishing Group is organizing “ International Conference & Exhibition on Virology ", will be held during 5-7 September 2011 Baltimore, USA. Virology-2011 is a specially designed cluster conference, which covers a wide range of critically important sessions in basic virology research to Advances in Cancer, Agriculture, Veterinary and Clini...
Source: The Journal of Infection in Developing Countries: Announcements - March 7, 2011 Category: Infectious Diseases Source Type: news

News: International Conference & Exhibition on Virology
Dates: 5 - 7 September 2011 Venue: Baltimore, USAWebsite: http://www.omicsonline.org/virology2011/Operated by: Editors-Journal of Antivirals& Antiretrovirals and Journal of AIDS& Clinical ResearchHosting Organization: OMICS Publishing Group OMICS Publishing Group is organizing “International Conference& Exhibition on Virology", will be held during 5-7 September 2011 Baltimore, USA. Virology-2011 is a specially designed cluster conference, which covers a wide range of critically important sessions in basic virology research to Advances in Cancer, Agriculture, Veterinary and Clinical research studies. ...
Source: The Journal of Infection in Developing Countries: Announcements - March 7, 2011 Category: Infectious Diseases Source Type: news